Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Anti-amyloid drugs are prescription antibody treatments for early Alzheimer's disease. Two are available in the US: lecanemab, sold as Leqembi, and donanemab, sold as Kisunla. Unlike older Alzheimer's medicines such as donepezil, which ease symptoms for a time, these drugs target a disease process in the brain and aim to slow how quickly memory, thinking and everyday abilities decline. They are meant for people at the earliest symptomatic stages: mild cognitive impairment (noticeable memory or thinking problems that don't yet prevent independent daily life) or mild dementia due to Alzheimer's. Before treatment, a test must confirm that amyloid is actually building up in the brain, usually an amyloid PET (positron emission tomography) scan, which shows amyloid in the brain, or a spinal fluid test. People with moderate or advanced dementia, or with memory problems from another cause, are not candidates. A third drug, aducanumab (Aduhelm), was the first of this group to be approved but was discontinued by its manufacturer in 2024 for business reasons, and is no longer available.
Amyloid beta is a protein fragment that, in Alzheimer's disease, clumps together and forms plaques between nerve cells in the brain. This buildup begins years before symptoms and is one of the defining features of the disease. Lecanemab and donanemab are monoclonal antibodies, laboratory-made immune proteins designed to latch onto a specific target. They bind to amyloid and help the body's immune system clear it, and scans show plaque levels falling substantially over the course of treatment. Removing amyloid does not repair brain cells that have already been lost, which is why these drugs slow decline rather than restore memory. Researchers are still working out how much amyloid removal, and which other disease changes, account for the benefit seen in trials.
Both drugs are given on a fixed schedule at an infusion center or clinic. Leqembi is given into a vein (intravenous infusion) over about an hour every two weeks, with the dose based on body weight. After 18 months, the care team may continue that schedule or switch to a maintenance schedule of one infusion every four weeks. Leqembi also comes as an autoinjector, Leqembi Iqlik, given as a weekly injection under the skin. After at least two doses given under a clinician's direct guidance, a person or caregiver may be able to give it at home. Kisunla is given as a roughly 30-minute infusion every four weeks, starting at a lower dose and stepping up over the first three infusions. Because donanemab clears plaques fairly quickly, the doctor may stop treatment once a PET scan shows amyloid has fallen to minimal levels, often after about a year to 18 months. Treatment involves more than the infusions. Before starting, people have a brain MRI (magnetic resonance imaging) scan and are usually offered a genetic test for APOE4 (explained under Interactions & Warnings). Further MRI scans are scheduled during the first months of treatment, before specific doses, to check for side effects in the brain. Missing these scans can mean a dose has to be postponed.
The most important side effect is amyloid-related imaging abnormalities (ARIA), changes that show up on brain scans. It means swelling in areas of the brain (ARIA-E) or small spots of bleeding in or on the surface of the brain (ARIA-H). ARIA is common: in the main Leqembi trial it appeared on scans in about 21% of people on the drug versus 9% on placebo, and rates with Kisunla are similar or somewhat higher. It usually happens in the first few months and most people have no symptoms, which is why routine MRIs are needed to find it. Around 3% of people develop symptoms. Rarely, ARIA or a larger bleed in the brain is serious, and deaths have occurred. This is the subject of a boxed warning, the most prominent safety warning the US Food and Drug Administration (FDA) requires. Contact the care team right away for a new or worsening headache, confusion, dizziness, vision changes, nausea or difficulty walking during treatment. A seizure, sudden weakness or trouble speaking needs emergency care. Infusion reactions, such as chills, flu-like aches, nausea, flushing or changes in blood pressure, are common, especially with the first few doses, and are usually mild. They can occur during the infusion or hours later; pretreatment with medicines like antihistamines or acetaminophen may help with later doses. Serious allergic reactions, including anaphylaxis, can happen, and swelling of the face or lips or trouble breathing needs emergency help. Headache is also common.
The risk of ARIA depends heavily on a gene called APOE. People who inherit two copies of its e4 version (about 15% of people with Alzheimer's) have much higher rates of ARIA, including serious ARIA, than people with one copy or none. In the Leqembi trial, people with two copies did not show a clear benefit on the main measure of decline. Testing is recommended before treatment, and because the result also says something about inherited Alzheimer's risk for relatives, it is worth discussing before the blood is drawn. Treatment is possible without testing, but the higher-risk group cannot then be identified. Blood thinners matter. Anticoagulants such as warfarin or apixaban (Eliquis) appear to raise the risk of serious bleeding in the brain during treatment, and the prescribing information advises particular caution for anyone who needs to stay on one. Aspirin and similar medicines should be reviewed with the prescriber too. Because ARIA can cause symptoms that look like a stroke, emergency teams need to know about the treatment before giving a clot-dissolving drug, which can cause dangerous bleeding in someone with ARIA. People on these drugs are advised to carry a card or note saying so. Doctors also look for MRI signs of fragile, amyloid-damaged blood vessels (cerebral amyloid angiopathy), previous brain bleeds or many small microbleeds, since these raise the risk enough that treatment is usually not advised.
These drugs do not stop or reverse Alzheimer's, and people do not usually notice improvement. In the trials, people on the drugs still declined, but more slowly: over about 18 months, decline on a standard rating of memory, thinking and daily function was about 27% slower with lecanemab and about 29% slower with donanemab than with placebo. In practical terms, that is a modest difference that may mean a little more time at the current level of independence. How long the benefit lasts beyond a few years, and whether it grows over time, is still being studied. The first months are the most demanding, with frequent visits and scheduled MRIs while the risk of ARIA is highest. Other Alzheimer's medicines, such as donepezil or memantine, were allowed alongside treatment in the trials. If ARIA appears, the doctor may pause doses until scans improve and then decide whether to resume. The decision to start is a balance of a modest slowing of decline against the time, travel, scans and brain-related risks involved. It is often made with a family member or caregiver, who may also help spot new symptoms.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Anti-amyloid Alzheimer's drugs, what you've noticed, or ask the community a question.